Vnitr Lek 2024, 70(8):513-516 | DOI: 10.36290/vnl.2024.098

Modern trends in asthma treatment

Samuel Genzor
Klinika plicních nemocí a TBC FN Olomouc a LF UP Olomouc
Centrum digitálního zdravotnictví FN Olomouc a LF UP Olomouc

Asthma bronchiale is a highly prevalent respiratory disease that reduces the quality of life of patients if the treatment is insufficient or ineffective. The mainstays of therapy are inhaled glucocorticoids, optimally in a fixed combination with long-acting beta-2-agonists. In case of insufficient effect, it is possible to consider increasing the dose of inhaled glucocorticoid, adding an antileukotriene, or adding long-acting anticholinergics. A patient with insufficiently controlled asthma on maximized treatment should be referred for precise diagnosis and medication adjustment to a specialized center for the treatment of difficult-to-treat asthma. The indication for the administration of biological/targeted treatment is also evaluated here.

Keywords: bronchial asthma, current recommendations, targeted treatment.

Accepted: November 27, 2024; Published: December 18, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Genzor S. Modern trends in asthma treatment. Vnitr Lek. 2024;70(8):513-516. doi: 10.36290/vnl.2024.098.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global strategy for Asthma Management and Prevention, GINA Main Report 2024. Available from https://ginasthma.org/2024-report/ (cit. 25. 8. 2024).
    2. Mortimer K, Lesosky M, García-Marcos L, et al. Global Asthma Network Phase I Study Group. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur Respir J. 2022 Sep 15;60(3):2102865 Go to original source... Go to PubMed...
    3. Asher MI, Rutter CE, Bissell K, et al. Global Asthma Network Phase I Study Group. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021 Oct 30;398(10311):1569-1580. Go to original source... Go to PubMed...
    4. Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020 Feb;42(1):5-15. Go to original source... Go to PubMed...
    5. Molnár D, Gálffy G, Horváth A, et al. Prevalence of Asthma and Its Associating Environmental Factors among 6-12-Year-Old Schoolchildren in a Metropolitan Environment-A Cross-Sectional, Questionnaire-Based Study. Int J Environ Res Public Health. 2021 Dec 20;18(24):13403. Go to original source... Go to PubMed...
    6. Papadopoulos NG, Miligkos M, Xepapadaki P. A Current Perspective of Allergic Asthma: From Mechanisms to Management. Handb Exp Pharmacol. 2022;268:69-93. Go to original source... Go to PubMed...
    7. Oppenheimer J, Hoyte FCL, Phipatanakul W, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022 Aug;129(2):169-180. Go to original source... Go to PubMed...
    8. Peri F, Amaddeo A, Badina L, et al. T2-Low Asthma: A Discussed but Still Orphan Disease. Biomedicines. 2023 Apr 20;11(4):1226. Go to original source... Go to PubMed...
    9. Janežič A, Locatelli I, Kos M. Inhalation technique and asthma outcomes with different corticosteroid-containing inhaler devices. J Asthma. 2020 Jun;57(6):654-662. Go to original source... Go to PubMed...
    10. Cote C, Pearle JL, Sharafkhaneh A, et al. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulmonary pharmacology & therapeutics. 2009 Feb 1;22(1):44-9. Go to original source... Go to PubMed...
    11. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr 16;55(4):1901872. Go to original source... Go to PubMed...
    12. Domingo C, Rello J, Sogo A. As-needed ICS-LABA in mild asthma: what does the evidence say?. Drugs. 2019 Nov;79(16):1729-37. Go to original source... Go to PubMed...
    13. Cusack RP, Satia I, O'Byrne PM. Asthma maintenance and reliever therapy: Should this be the standard of care? Ann Allergy Asthma Immunol. 2020 Aug;125(2):150-155. doi: 10.1016/j.anai.2020. 04. 009. Epub 2020 Apr 24. PMID: 32339657. Go to original source...
    14. Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma: a plain language summary of the MANDALA study. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241232264. Go to original source... Go to PubMed...
    15. Kistemaker LE, Oenema TA, Meurs H, et al. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012 Nov 27;91(21-22):1126-33. Go to original source... Go to PubMed...
    16. Cazzola M, Calzetta L, Rogliani P et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulmonary pharmacology & therapeutics. 2016 Feb 1;36:1-9. Go to original source... Go to PubMed...
    17. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023-1042. Go to original source... Go to PubMed...
    18. Li T, Yin J, Yang Y, et al. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives. Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):939-948. Go to original source... Go to PubMed...
    19. Kai M, Vion PA, Boussouar S, et al. Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature. RMD Open. 2023 Sep;9(3):e003300. Go to original source... Go to PubMed...
    20. Caminati M, Buhl R, Corren J, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 May;79(5):1134-1145. doi: 10.1111/all.15986. Go to original source... Go to PubMed...
    21. Chagas GCL, Xavier D, Gomes L, et al. Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis. Curr Allergy Asthma Rep. 2023 Jun;23(6):287-298. Go to original source... Go to PubMed...
    22. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. Go to original source... Go to PubMed...
    23. Chan R, Stewart K, Misirovs R, et al. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1497-1505. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.